|
Abstract
|
Then, the pHresponsive
manner of both nanocomposites was proved by checking their release profiles at pH
of the physiological environment (pH 7.4) and pH of tumor tissues (mildly acidic). Finally, the
potential antitumoral activity of these nanocomposite systems against MCF7 cell lines was
evaluated by MTT assay and cell cycle studies. The results demonstrated that the novel
Accepted Manuscript
developed nanocomposites not only meet our expectations about simultaneous release of two
anticancer drugs according to the predicted profile but also showed antibacterial and anticancer
properties in vitro experimental. Moreover, it was proved that these carriers have tremendous
potential in multifunctional drug delivery in cancer therapy.
|